skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Metoprolol succinate extended release/hydrochlorothiazide combination tablets

(2969) Views  (1424) Full article downloads

Authors: James W Hainer, Jennifer Sugg

Published Date August 2007 Volume 2007:3(3) Pages 279 - 288
DOI: http://dx.doi.org/10.2147/VHRM.S

James W Hainer, Jennifer Sugg

AstraZeneca LP, Wilmington, DE, USA

Abstract: Lowering elevated blood pressure (BP) with drug therapy reduces the risk for catastrophic fatal and nonfatal cardiovascular events such as stroke and myocardial infarction. Given the heterogeneity of hypertension as a disease, the marked variability in an individual patient’s BP response, and low response rates with monotherapy, expert groups such as the Joint National Committee (JNC) emphasize the value of combination antihypertensive regimens, noting that combinations, usually of different classes, have additive antihypertensive effects. Metoprolol succinate extended-release tablet is a beta-1 (cardio-selective) adrenoceptor-blocking agent formulated to provide controlled and predictable release of metoprolol. Hydrochlorothiazide (HCT) is a well-established diuretic and antihypertensive agent, which promotes natruresis by acting on the distal renal tubule. The pharmacokinetics, efficacy, and safety/tolerability of the antihypertensive combination tablet, metoprolol extended release hydrochlorothiazide, essentially reflect the well-described independent characteristics of each of the component agents. Not only is the combination product more effective than monotherapy with the individual components but the combination product allows a low-dose multidrug regimen as an alternative to high-dose monotherapy, thereby, minimizing the likelihood of dose-related side-effects.

Keywords: antihypertensive, blood pressure, cardiovascular disease, combination product








Readers of this article also read:

Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns
Preventing stroke in atrial fibrillation patients – clinical utility of oral anticoagulants
Liraglutide therapy beyond glycemic control: An observational study in Indian patients with type 2 diabetes in real world setting
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University